Company intelligence / Profile preview
ViMREX GmbH
Heidelberg, Baden-Württemberg, Germanyvimrex.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ViMREX is developing a local therapy against HPV-induced precancerous lesions using demethylating agents. The company has identified a molecular mechanism by which HPV alters cells to become malignant and has identified a drug class that may revert this situation. They are planning and conducting clinical Phase I and Phase IIa studies on patients with precancerous HPV-induced vulvar intraepithelial neoplasia[1][5].
- Therapeutic areas
- Women's HealthOncology
- Modalities
- Demethylating agents
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on ViMREX GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViMREX GmbH.